Mizuho Asset Management Co. Ltd. raised its stake in C.R. Bard Inc. (NYSE:BCR) by 75.0% during the second quarter, Holdings Channel reports. The fund owned 898 shares of the company’s stock after buying an additional 385 shares during the period. Mizuho Asset Management Co. Ltd.’s holdings in C.R. Bard were worth $211,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in BCR. Standard Life Investments LTD acquired a new stake in C.R. Bard during the second quarter valued at approximately $241,642,000. Norges Bank acquired a new stake in C.R. Bard during the fourth quarter valued at approximately $123,663,000. JPMorgan Chase & Co. increased its stake in C.R. Bard by 353.4% in the first quarter. JPMorgan Chase & Co. now owns 667,533 shares of the company’s stock valued at $135,290,000 after buying an additional 520,319 shares during the last quarter. Bank of Montreal Can acquired a new stake in C.R. Bard during the second quarter valued at approximately $96,292,000. Finally, Vanguard Group Inc. increased its stake in C.R. Bard by 4.7% in the second quarter. Vanguard Group Inc. now owns 7,413,815 shares of the company’s stock valued at $1,743,433,000 after buying an additional 335,276 shares during the last quarter. Institutional investors own 87.90% of the company’s stock.
C.R. Bard Inc. (NYSE:BCR) traded down 0.094% during midday trading on Wednesday, reaching $227.745. The company’s stock had a trading volume of 66,430 shares. The stock’s 50-day moving average price is $220.20 and its 200 day moving average price is $217.61. C.R. Bard Inc. has a 1-year low of $172.21 and a 1-year high of $239.43. The firm has a market capitalization of $16.73 billion, a PE ratio of 52.964 and a beta of 0.57.
C.R. Bard (NYSE:BCR) last posted its earnings results on Tuesday, July 26th. The company reported $2.54 EPS for the quarter, beating the Zacks’ consensus estimate of $2.47 by $0.07. C.R. Bard had a return on equity of 48.43% and a net margin of 9.20%. The company had revenue of $931.50 million for the quarter, compared to the consensus estimate of $915.22 million. During the same quarter in the previous year, the business earned $2.27 earnings per share. The company’s revenue for the quarter was up 8.3% on a year-over-year basis. Equities analysts anticipate that C.R. Bard Inc. will post $10.17 EPS for the current fiscal year.
A number of equities research analysts have issued reports on the company. Bank of America Corp. downgraded C.R. Bard from a “buy” rating to a “neutral” rating in a research note on Friday, July 8th. Wells Fargo & Co. upgraded C.R. Bard from a “market perform” rating to an “outperform” rating in a research note on Friday, September 16th. Zacks Investment Research downgraded C.R. Bard from a “buy” rating to a “hold” rating in a research note on Thursday, August 4th. Leerink Swann restated a “market perform” rating and set a $233.00 price target (down from $240.00) on shares of C.R. Bard in a research note on Thursday, July 28th. Finally, Barclays PLC boosted their price target on C.R. Bard from $212.00 to $224.00 and gave the company an “equal weight” rating in a research note on Tuesday, May 24th. Thirteen research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $233.00.
In other C.R. Bard news, VP Betty D. Larson sold 4,032 shares of C.R. Bard stock in a transaction on Monday, September 19th. The stock was sold at an average price of $225.33, for a total value of $908,530.56. Following the sale, the vice president now owns 10,298 shares in the company, valued at $2,320,448.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP John A. Deford sold 7,928 shares of C.R. Bard stock in a transaction on Tuesday, September 6th. The shares were sold at an average price of $221.06, for a total value of $1,752,563.68. The disclosure for this sale can be found here. 0.97% of the stock is owned by company insiders.
About C.R. Bard
C. R. Bard, Inc (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities.
Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard Inc. (NYSE:BCR).
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.